文献速递流行病学与生物统计临床试验与 GCP

随机双盲对照试验中非劣效界值定义方法的系统综述

Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review.
PubMed 文献 · Trials · 2017-03-07

该系统综述检索1966年1月1日至2015年2月6日PubMed发表的随机双盲非劣效试验,纳入273篇文章共273个非劣效界值,分析界值定义方法及报告随时间的变化。结果显示基于历史证据定义界值并不常见,且报告率低;2010年FDA指南草案发布与固定界值法报告增加相关。

要点

  • 共纳入273篇文章,对应273个非劣效界值。
  • 基于历史证据定义界值与采用其他方法定义的界值数量无显著差异(比值2.17,95%CI 0.86至5.82,p=0.11)。
  • 界值定义方法未报告与已报告的数量相似(比值1.35,95%CI 0.76至2.43,p=0.31)。

核心结论

  • 非劣效界值不常基于阳性对照的历史证据定义,且报告质量差。
  • 作者、审稿人和编辑需要关注报告这一关键信息,以便更好地评判非劣效试验。

研究设计与样本

  • 系统综述,检索PubMed从1966年1月1日至2015年2月6日发表的随机双盲非劣效试验,纳入273篇文章,对应273个非劣效界值。
  • 主要结局为基于历史证据以外方法定义的界值数量,并评估时间趋势;次要结局为界值定义方法未报告情况及其随时间变化;采用Poisson对数线性模型分析,并采用logistic回归分析更好报告方法的预测因素及固定界值法的使用。

主要发现

  • 基于其他方法定义的界值与基于历史证据定义的界值数量无统计学显著差异(比值2.17,95%CI 0.86至5.82,p=0.11),且不随时间变化。
  • 界值定义方法未报告的数量与已报告的数量相似(比值1.35,95%CI 0.76至2.43,p=0.31),不随时间变化。
  • 低影响因子期刊相比高影响因子期刊,界值定义方法报告更少(OR 0.20;95%CI 0.10至0.37,p<0.0001)。
  • 2010年FDA指南草案发布与固定界值法报告增加相关(2010年后 vs 2010年前,OR 3.54;95%CI 1.12至13.35,p=0.04)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is no consensus on the preferred method for defining the non-inferiority margin in non-inferiority trials, and previous studies showed that the rationale for its choice is often not reported. This study investigated how the non-inferiority margin is defined in the published literature, and whether its reporting has changed over time. METHODS: A systematic PubMed search was conducted for all published randomized, double-blind, non-inferiority trials from January 1, 1966, to February 6, 2015. The primary outcome was the number of margins that were defined by methods other than the historical evidence of the active comparator. This was evaluated for a time trend. We also assessed the under-reporting of the methods of defining the margin as a secondary outcome, and whether this changed over time. Both outcomes were analyzed using a Poisson log-linear model. Predictors for better reporting of the methods, and the use of the fixed-margin method (one of the historical evidence methods) were also analyzed using logistic regression. RESULTS: Two hundred seventy-three articles were included, which account for 273 non-inferiority margins. There was no statistically significant difference in the number of margins that were defined by other methods compared to those defined based on the historical evidence (ratio 2.17, 95% CI 0.86 to 5.82, p = 0.11), and this did not change over time. The number of margins for which methods were unreported was similar to those with reported methods (ratio 1.35, 95% CI 0.76 to 2.43, p = 0.31), with no change over time. The method of defining the margin was less often reported in journals with low-impact factors compared to journals with high-impact factors (OR 0.20; 95% CI 0.10 to 0.37, p < 0.0001). The publication of the FDA draft guidance in 2010 was associated with increased reporting of the fixed-margin method (after versus before 2010) (OR 3.54; 95% CI 1.12 to 13.35, p = 0.04). CONCLUSIONS: Non-inferiority margins are not commonly defined based on the historical evidence of the active comparator, and they are poorly reported. Authors, reviewers, and editors need to take notice of reporting this critical information to allow for better judgment of non-inferiority trials.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Althunian TA, de Boer A, Klungel OH, et al. Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. Trials. 2017. PMID: 28270184. doi:10.1186/s13063-017-1859-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。